TrialAdvances in therapy2018

Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.

Yuichiro Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.